Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Flurandrenolide
Overview
What is Cordran?
Cordran Tape (Flurandrenolide Tape, USP) is a transparent, inconspicuous, plastic surgical tape. It contains Cordran (Flurandrenolide, USP), a potent corticosteroid for topical use. Flurandrenolide occurs as white to off-white, fluffy crystalline powder and is odorless. Flurandrenolide is practically insoluble in water and in ether. One g dissolves in 72 mL of alcohol and in 10 mL of chloroform. The molecular weight of flurandrenolide is 436.52.
The chemical name of flurandrenolide is Pregn-4-ene-3,20-dione, 6-fluoro-11,21 dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (6α, 11ß, 16α)-; its empirical formula is CHFO. The structural formula is as follows:
Each square centimeter contains 4 μg (0.00916 μmol) flurandrenolide uniformly distributed in the adhesive layer. The tape is made of a thin, matte-finish polyethylene film that is slightly elastic and highly flexible.
The adhesive is a synthetic copolymer of acrylate ester and acrylic acid that is free from substances of plant origin. The pressure-sensitive adhesive surface is covered with a protective paper liner to permit handling and trimming before application.
What does Cordran look like?
What are the available doses of Cordran?
Sorry No records found.
What should I talk to my health care provider before I take Cordran?
Sorry No records found
How should I use Cordran?
For relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, particularly dry, scaling localized lesions.
Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions.
If an infection develops, the use of Cordran Tape and other occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.
Replacement of the tape every 12 hours produces the lowest incidence of adverse reactions, but it may be left in place for 24 hours if it is well tolerated and adheres satisfactorily. When necessary, the tape may be used at night only and removed during the day.
If ends of the tape loosen prematurely, they may be trimmed off and replaced with fresh tape.
The directions given below are included for the patient to follow unless otherwise instructed by the physician.
________________________________________________________________________
APPLICATION OF CORDRAN TAPE
DIRECTIONS FOR USE:
Keep Cordran Tape in the original container. Do not repackage. Protect from moisture. Keep vial tightly closed in a dry place.
REPLACEMENT OF TAPE:
Unless instructed otherwise by your physician, replace tape after 12 hours. Cleanse skin and allow it to dry for 1 hour before applying new tape.
IF IRRITATION OR INFECTION DEVELOPS, REMOVE TAPE AND CONSULT PHYSICIAN.
________________________________________________________________________
What interacts with Cordran?
Sorry No Records found
What are the warnings of Cordran?
Sorry No Records found
What are the precautions of Cordran?
Sorry No Records found
What are the side effects of Cordran?
Sorry No records found
What should I look out for while using Cordran?
Topical corticosteroids are contraindicated in patients with a history of hypersensitivity to any of the components of these preparations.
Use of Cordran Tape is not recommended for lesions exuding serum or in intertriginous areas.
What might happen if I take too much Cordran?
Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (
).
How should I store and handle Cordran?
Store at 20° to 25°C (68° to 77°F); excursions permitted from 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Tape:4 mcg/sq cm—small roll, 24 in x 3 in (60 cm x 7.5 cm), in a flip-top vial 4 mcg/sq cm—large roll, 80 in x 3 in (200 cm x 7.5 cm), in a flip-top vial Store at 20-25°C (68-77°F). [See USP controlled room temperature.]Keep out of reach of children.Rx onlyTape:4 mcg/sq cm—small roll, 24 in x 3 in (60 cm x 7.5 cm), in a flip-top vial 4 mcg/sq cm—large roll, 80 in x 3 in (200 cm x 7.5 cm), in a flip-top vial Store at 20-25°C (68-77°F). [See USP controlled room temperature.]Keep out of reach of children.Rx onlyTape:4 mcg/sq cm—small roll, 24 in x 3 in (60 cm x 7.5 cm), in a flip-top vial 4 mcg/sq cm—large roll, 80 in x 3 in (200 cm x 7.5 cm), in a flip-top vial Store at 20-25°C (68-77°F). [See USP controlled room temperature.]Keep out of reach of children.Rx onlyTape:4 mcg/sq cm—small roll, 24 in x 3 in (60 cm x 7.5 cm), in a flip-top vial 4 mcg/sq cm—large roll, 80 in x 3 in (200 cm x 7.5 cm), in a flip-top vial Store at 20-25°C (68-77°F). [See USP controlled room temperature.]Keep out of reach of children.Rx onlyTape:4 mcg/sq cm—small roll, 24 in x 3 in (60 cm x 7.5 cm), in a flip-top vial 4 mcg/sq cm—large roll, 80 in x 3 in (200 cm x 7.5 cm), in a flip-top vial Store at 20-25°C (68-77°F). [See USP controlled room temperature.]Keep out of reach of children.Rx onlyTape:4 mcg/sq cm—small roll, 24 in x 3 in (60 cm x 7.5 cm), in a flip-top vial 4 mcg/sq cm—large roll, 80 in x 3 in (200 cm x 7.5 cm), in a flip-top vial Store at 20-25°C (68-77°F). [See USP controlled room temperature.]Keep out of reach of children.Rx only
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Cordran is primarily effective because of its anti-inflammatory, antipruritic, and vasoconstrictive actions.
The mechanism of the anti-inflammatory effect of topical corticosteroids is not completely understood. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man. Corticosteroids with anti-inflammatory activity may stabilize cellular and lysosomal membranes. There is also the suggestion that the effect on the membranes of lysosomes prevents the release of proteolytic enzymes and, thus, plays a part in reducing inflammation.
The tape serves as both a vehicle and an occlusive dressing. Retention of insensible perspiration by the tape results in hydration of the stratum corneum and improved diffusion of the medication. The skin is protected from scratching, rubbing, desiccation, and chemical irritation. The tape acts as a mechanical splint to fissured skin. Since it prevents removal of the medication by washing or the rubbing action of clothing, the tape formulation provides a sustained action.
Pharmacokinetics
Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses (
).
Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to those of systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. They are metabolized primarily in the liver and then excreted in the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.
Non-Clinical Toxicology
Topical corticosteroids are contraindicated in patients with a history of hypersensitivity to any of the components of these preparations.Use of Cordran Tape is not recommended for lesions exuding serum or in intertriginous areas.
See . Misoprostol Tablets has not been shown to interfere with the beneficial effects of aspirin on signs and symptoms of rheumatoid arthritis. Misoprostol Tablets does not exert clinically significant effects on the absorption, blood levels, and antiplatelet effects of therapeutic doses of aspirin. Misoprostol Tablets has no clinically significant effect on the kinetics of diclofenac or ibuprofen.
Prostaglandins such as Misoprostol Tablets may augment the activity of oxytocic agents, especially when given less than 4 hours prior to initiating oxytocin treatment. Concomitantuse is not recommended.
Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients.
Conditions that augment systemic absorption include application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings.
Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using urinary-free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.
Recovery of HPA axis function is generally prompt and complete on discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, so that supplemental systemic corticosteroids are required.
Pediatric patients may absorb proportionately larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity ( under ).
If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.
In the presence of dermatologic infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, Cordran should be discontinued until the infection has been adequately controlled.
The following local adverse reactions are reported infrequently with topical corticosteroids but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis.
The following may occur more frequently with occlusive dressings: maceration of the skin, secondary infection, skin atrophy, striae, miliaria.
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
516Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).